Buradasınız

Anasayfa » Content

TEDAVİYE DÎRENÇLÎ PRÎMER GLOMERULER HASTALIKLARDA MÎKOFENOLAT MOFETİL KULLANIMI (RETROSPEKTİF ANALİZ)

MYCOPHENOLATE MOFETİL TREATMENT IN PRIMARY GLOMERULONEPHRITIS THAT IS RESISTANT TO TREATMENT (RETROSPECTIVE ANALYSIS)

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The success rate of different treatment protocols for primary glomerulonephritis (PGN) is 60-70%. Recently, it has been suggested that in somel patients who are unresponsive to standard treatments, \ mycophenolate mofetil (MMF)- the pro-drug of mycophenolic acid- can be used. In our study, the \ results of 20 patients suffering from PGN (7 membranous nephropathy, 6 membranoproliferative GN, 3 focal segmentary glomerulosclerosis, 2 Ig A nephropathy, 1 proliferative GN and 1 mesangioproliferative GN) are investigated. The patients that were given MMF for 2-13 months (mean 7.35 months) were followed up for 8.95 month on the j average and given MMF l-2g/day. In the patients that \ had proliferative lesion (membranoproliferative GN, \ Ig A nephropathy, proliferative and\ mesangioproliferative GN) in histopathological"\ examination the complete response rate was found\ 70% whereas in the patients that did not have proliferative lesion, it was found 30%. Apart from this, in 3 patients the steroid sparing effect of MMF was observed while no serious side effect was noted. In conclusion, MMF is a well tolerable new \ immunosuppressive drug that enables steroid dose: reduction and can be effective in the treatment of PGNs in which proliferative lesion is prominent. The \ prospective, controlled and large studies about this subject would be exciting.
Bookmark/Search this post with
Abstract (Original Language): 
Primer glomerulonefrit (PGN) 'lerin tedavisinde kullanılan değişik protokollerin başarı oranı %60-70 'dır. Son yıllarda standart tedavilere yanıtsız bazı hastalarda, mikofenolatın önilacı olan mikofenolat mofetil (MMF) 'in kullanılabileceği bildirilmektedir. Çalışmamızda MMF kullanılan PGNli 20 hasta (7 membranöz nefropati, 6 membranoproliferatif GN, 3 fokal segmental glomeruloskleroz, 2 IgA nefropatisi, 1 proliferatif GN ve 1 mezangiyoproliferatiif GN) 'nın sonuçları incelenmiştir. Ortalama 7.35 (2-13) ay MMF verilen hastalar ortalama 8.95 ay izlenmiş olup MMF 1-2g/gün arasında verilmiştir. Histopatolojisinde proliferatif lezyonu olan (membranoproliferatif GN, IgA nefropatisi, proliferatif ve mezangiyoproliferatif GN) hastaların tam yanıt oranı %70, proliferatif lezyonu olmayanların ise %30 bulunmuştur. Ayrıca 3 hastada MMF'nin steroid doz-azaltıcı etkinliğinin olduğu görülürken hiçbir hastada ciddi yan etkiye rastlanılmamıştır. Sonuç olarak MMF, proliferatif lezyonu ön planda olan PGN'lerin tedavisinde etkili olabilen, steroid doz azaltımına olanak sağlayan ve iyi tolere edilen yeni bir immunosupressif ilaçtır ve bu konuda geniş çaplı kontrollü ve prospektif çalışmalar yapılması heyecan verici olacaktır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_384.pdf
  • 2
93-98
  • Turkish

REFERENCES

References: 

1. Johnson JR., Feehally J., Texbook of Comprehensive Clinical Nephrology, Harcourt Publishers Limited, Barcelona, 2000,20.1-8.
2. Briggs WA., Choi MJ., et al. Successful mycophenolate mofetil treatment of glomerular disease. Am. J. Kidney Dis. 1998, Feb;31(2):213-7.
3. Jayne D, Non-transplant uses of Mycophenolate Mofetil. Current Opinion in Nephrology and Hypertension, 1999,8:563-567.
4. Briggs WA., Choi MJ., et al. Follow-up on mycophenolate mofetil treatment of glomerular disease.
Am. J. Kidney Dis. 1998, Feb;31(2):898-899
5. Miller G.; Zimmerman R.;et al. Use of mycophenolate mofetil in resistant membranous nephropathy. Am. J.
Kidney Dis. 2000, Aug;36(2):250-6.
6. Brenner's and Rector's The Kidney, Sixth Edition, ,
2000 1272-1303.
7. Van Bruggen MC, Walgreen B., Attenuation of murine lupus nephritis by mycophenolate mofetil. J. Am. Soc.
Nephrol., 1998, 9(8):1407-15.
8. Jonsson CA., Svensson L., Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin. Exp. Immunol.
1999, 116(3):534-41.
9. Coma D., Morigi M., Mycophenolate mofetil limits renal damage and prolongs life in murine lupus
autoimmune dissease. Kidney int., 1997,51(5): 1583-9.
10. Dooley MA., Cosio FG.,et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J. Am.
Soc. Nephrol., 1999, 10(4):833-9.
11. Ziswiler R., Steinmann-Niggli K., Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J. Am. Soc.
Nephrol., 1998, 9(11 ):2055-66.
12. Gregory CR., Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation, 1995, 15; 59(5): 655-61.
13. Badid C, Vincent M., et al. Mycophenolate mofetil reduces interstitial myofibroblast infiltration and
collagen III depozit. Kidney Int., 2000, 58:51-61.
14. Chan TM., Li F., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med., 2000, 19;343( 16): 1156-62.
15. Radhakrishnan J., Wang MM., al. Mycophenolate mofetil treatment of idiopatic focal segmental glomerulosclerosis. J. Am. Soc. Nephrol., 1999, 114A
(abstract A584).
16. Al-Lehbi AM., Al-Mutairi MA., et al. Mycophenolate
mofetil in steroid resistant focal segmental glomerulosclerosis. J. Am. Soc. Nephrol., 1999, 94A
(abstract A483).

Thank you for copying data from http://www.arastirmax.com